The loss of Aerie Pharmaceuticals under GAAP for the 3 months of 2022 was $35.891 million, down 14.5% compared to $41.964 million in the previous year. Revenue increased 29.9% to $29.835 million from $22.97 million a year earlier.
The loss of Aerie Pharmaceuticals under GAAP for the 3 months of 2022 was $35.891 million, down 14.5% compared to $41.964 million in the previous year. Revenue increased 29.9% to $29.835 million from $22.97 million a year earlier. 
investors.aeriepharma.com
English (US) 